Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
NEJM Journal Watch Oncology and Hematology Top Stories of 2022
This year, our list of top stories includes coverage of studies on breast, lung, gastrointestinal, and genitourinary cancers as well as malignant and benign hematology. It is always challenging to identify only 10 key papers from the universe of important new data, but these summaries underscore our goal of identifying the most clinically relevant trials and highlighting their key findings and implications.
We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.
The top NEJM Journal Watch Oncology and Hematology stories for 2022 are:
Avoiding Chemotherapy in ER-Positive, Node-Positive Breast Cancer
Immunotherapy plus Chemotherapy Before Surgery Improves Outcomes in Lung Cancer
Evolving Management for Locally Advanced Prostate Cancer
Cervical Cancer: Immunotherapy for All?
Pembrolizumab Is a New Standard for Early-Stage TNBC
Time for Targeted Treatment in Low-Grade Serous Ovarian Cancer?
DESTINY-Breast03: Improving Outcomes in Metastatic HER2-Positive Breast Cancer
Risks of Steroid Use in Patients with Sickle Cell Disease
PD-1 Inhibitor Effective in MSI-High Locally Advanced Rectal Cancer
COVID-19 Vaccine Booster Responses in Patients with Hematologic Malignancies
Empfohlen von
William J. Gradishar, MD